INT71649

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1997
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 23
Total Number 23
Disease Relevance 13.63
Pain Relevance 0.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERBB2) signal transduction (ERBB2) plasma membrane (ERBB2)
nucleus (ERBB2) cytoplasm (ERBB2)
Anatomy Link Frequency
lymph nodes 1
capsules 1
heart 1
urine 1
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 96 94.24 High High
addiction 10 93.32 High High
alcohol 5 85.40 High High
cytokine 20 80.96 Quite High
Pain 12 75.00 Quite High
palliative 14 72.96 Quite High
carbamazepine 4 68.32 Quite High
dexamethasone 4 67.12 Quite High
tolerance 10 61.28 Quite High
opiate 4 14.12 Low Low
Disease Link Frequency Relevance Heat
Cancer 1178 100.00 Very High Very High Very High
Disease 342 100.00 Very High Very High Very High
Targeted Disruption 14 97.68 Very High Very High Very High
Breast Cancer 733 97.24 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 220 96.08 Very High Very High Very High
Aggression 6 96.04 Very High Very High Very High
Hemolysis 2 95.68 Very High Very High Very High
Stomach Cancer 190 95.36 Very High Very High Very High
Carcinoma 29 94.68 High High
INFLAMMATION 90 94.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In preclinical models as well, cyclophosphamide, doxorubicin, and paclitaxel have all been shown to enhance the antitumor immune response elicited with a GM-CSF-secreting, HER2/neu-expressing whole-tumor cell vaccine in tumor bearing neu-transgenic mice [89].
Localization (secreting) of HER2/neu associated with targeted disruption and cancer
1) Confidence 0.78 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2840411 Disease Relevance 1.04 Pain Relevance 0.08
HER-2/neu (HER2) is a proto-oncogene located on chromosome 17q21 and a member of the human epidermal growth factor receptor (EGFR) family.
Localization (located) of HER2
2) Confidence 0.75 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.00 Pain Relevance 0.07
In this trial, patients with gastroesophageal cancer (n = 3,807) were centrally tested for HER2 status by IHC and FISH (patients were eligible if their tumor samples were scored as 3+ on IHC or if they were FISH positive (HER2:CEP17 ratio ?
Localization (eligible) of HER2 associated with cancer
3) Confidence 0.75 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.04 Pain Relevance 0
HER-2/neu (HER2) is a proto-oncogene located on chromosome 17q21 and a member of the human epidermal growth factor receptor (EGFR) family.
Localization (located) of HER-2
4) Confidence 0.75 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.00 Pain Relevance 0.07
Inclusion of taxanes, aromatase inhibitors, as well as trastuzumab (for HER2-positive disease) becomes implemented at these levels as well.
Localization (disease) of HER2 associated with disease
5) Confidence 0.73 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC3010663 Disease Relevance 0.83 Pain Relevance 0.05
HER1/HER2 and response
Localization (response) of HER1/HER2
6) Confidence 0.71 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.36 Pain Relevance 0
There is increasing experimental evidence supporting a direct toxic effect of HER2 blockade on the heart.
Localization (blockade) of HER2 in heart
7) Confidence 0.70 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1959236 Disease Relevance 0.45 Pain Relevance 0.05
While the sequential administration of trastuzumab after chemotherapy appears to be effective, longer follow- up is needed to determine whether simultaneous and sequential administration with other chemotherapy agents are equally effective and whether there is a population of patients in whom chemotherapy is not necessary (patients with estrogen receptor-positive and HER-2/neu-positive disease, patients with negative lymph nodes and tumors < 1 cm) and for whom trastuzumab alone might represent appropriate adjuvant therapy.
Localization (disease) of HER-2 in lymph nodes associated with cancer and disease
8) Confidence 0.70 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1959236 Disease Relevance 0.46 Pain Relevance 0
These patients are small in number and were not randomized by HER2 status, but they were well balanced between the treatment groups.
Neg (not) Localization (randomized) of HER2
9) Confidence 0.70 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.33 Pain Relevance 0
We await results of the phase III trial assessing lapatinib and paclitaxel, with background retrospective analyses favoring the combination therapy in HER2 positive disease.
Localization (disease) of HER2 associated with disease
10) Confidence 0.70 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 1.10 Pain Relevance 0.03
Geldanamycin could be included in the panel of potential therapeutic tools because it destabilizes ERBB2 tyrosine kinase and suppresses WNT/?
Localization (kinase) of ERBB2
11) Confidence 0.69 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.66 Pain Relevance 0.11
The expression of pERBB2 could help predict clinical response of ERBB2-positive BCs to trastuzumab or lapatinib [8,42,43]. pERBB2 status was evaluated by IHC on 22 ERBB2-amplified samples (Figure 5) and was detected in 17/22 (Additionnal file 1-Tables S8-S9A).
Localization (response) of ERBB2
12) Confidence 0.69 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.12 Pain Relevance 0
The optimal titer for each antibody (except for HercepTest and G11 directed against ERBB2 and IGF1R, Additionnal file 1-Table S2) was established based on negative and positive controls.
Localization (directed) of ERBB2
13) Confidence 0.69 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.10 Pain Relevance 0.04
HER-2/neu (HER2) is a proto-oncogene located on chromosome 17q21 and a member of the human epidermal growth factor receptor (EGFR) family.
Localization (located) of neu
14) Confidence 0.65 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.00 Pain Relevance 0.07
ER/PR-negative tumors are often associated with aggressive disease, and these tumors frequently show amplification of HER2, c-Myc, and Int2 oncogenes, and mutations of the p53 tumor suppressor gene.
Localization (amplification) of HER2 associated with cancer and disease
15) Confidence 0.65 Published 2010 Journal Clinical Medicine Insights. Oncology Section Body Doc Link PMC2883240 Disease Relevance 1.13 Pain Relevance 0.11
Therefore, while results of preoperative targeting of Her2 and its amplicon are definitely encouraging, the neoadjuvant approach with trastuzumab still remains largely experimental.
Localization (targeting) of Her2
16) Confidence 0.65 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721347 Disease Relevance 0.18 Pain Relevance 0
These observations suggest that HER-2 is an appropriate target for
Localization (target) of HER-2
17) Confidence 0.63 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.71 Pain Relevance 0
Although both EGFR and HER-2 (+ve) are
Localization (+ve) of HER-2
18) Confidence 0.63 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.50 Pain Relevance 0
which is capable of targeting both the EGFR and HER-2/neu tyrosine kinases that
Localization (targeting) of HER-2
19) Confidence 0.63 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.40 Pain Relevance 0
Serum concentrations of lapatinib are limited by low solubility, low permeability and extensive first pass metabolism by cytochrome P-450 enzymes CYP3A4 and CYP3A5, and to a lesser extent by CYP2C19 and CYP2C8.7 One metabolite (GW690006) remains active against EGFR but not HER2.8 Less than 2% of lapatinib is excreted in the urine.
Localization (excreted) of HER2 in urine
20) Confidence 0.61 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox